[Acute portal thrombosis in patients with hepatitis C treated with pegylated interferon and ribavirin].
The combination of pegylated interferon and ribavirin is the first option treatment for chronic hepatitis C (HCC). Although not frequent, several vascular adverse events, such as Raynaud's phenomenon, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome and central retinal vein occlusion, have been associated with the use of pegylated and standard interferon. We report the cases of two patients with HCC who, while receiving treatment with pegylated interferon and ribavirin, developed decompensated liver disease. Radiological tests revealed acute portal thrombosis. After the diagnosis was established, anticoagulant therapy was started, which resolved the portal thrombosis.
Merino Rodríguez
Beatriz
B
Sección de Hepatología, Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, España.
Díaz Sánchez
Antonio
A
Matilla Peña
Ana
A
Clemente Ricote
Gerardo
G
Núñez Martínez
Oscar
O
D000208:Acute Disease; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011169:Portal Vein; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D013927:Thrombosis / Q000139:chemically induced*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a